Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises

Executive Summary

With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.

Advertisement

Related Content

Medivation Sees Potential For Combinations Out Of Opdivo Failure
PD-1 Progress May Shorten The Life Of Other Drugs
Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa
AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel